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Abstract 
Osteoporosis occurs commonly in homocystinuria. The underlying pathobiochemical mechanism remains unclear: disturbed cross-lin- 
king of collagen has been suggested but this hypothesis has not been fully tested, nor have studies on collagen synthesis been performed. 
We therefore used recently available noninvasive tests for collagen synthesis and cross-linking to examine 10 patients with homocystin- 
uria. Synthesis of collagen type I and type III was not different from age-matched healthy controls as reflected by comparable plasma 
levels of carboxyterminal propeptide of type I procollagen (PICP) and of plasma levels of N-terminal propeptide of procollagen type III 
(PIIINP). Collagen type I cross-links expressed by serum carboxyterminal te opeptide of collagen type I (ICTP) were 1.14 _+ 0.24/xg/l in 
the patient group versus 3.29 _+ 0.32 /xg/1 in the control group. This significant reduction of cross-links in the group with homocystinuria 
did not correlate with serum homocysteine orhomocysteic acid concentrations. Our data clearly indicate that the disturbed cross-linking 
hypothesis till holds and that the bone manifestations of homocystinuria are not due to deficient collagen synthesis. 
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1. Introduction 
Patients with homocystinuria develop osteoporosis, ub- 
luxation of the ocular lens, mental retardation and vascular 
disease; the overall risk of these patients developing osteo- 
porosis has been reported to be 50% by age 16 [1]. 
McKusick first proposed that excess homocysteine might 
interfere with the normal synthesis of collagen cross-links 
[2] and some indirect evidence for this hypothesis was 
provided by the finding of increased acid solubility of 
collagen from skin biopsies in two out of four patients 
with homocystinuria [3]. Homocystinuric patients present- 
ing with decreased precursor aldehydes of skin collagen 
have been described [4]. 
A mechanism similar to that reported for D-penicilla- 
mine, which shows structural analogy with homocysteine, 
has also been proposed. D-penicillamine decreases collagen 
solubility by blocking lysyl- or hydroxylysyl aldehyde 
residues which are known cross-link precursors [5]. Inhibi- 
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tion of the formation of Schiff base bifunctional cross-links 
has been suggested as well [6]. In vitro studies have shown 
that homocysteine inhibits cross-linking and fibril forma- 
tion of isolated collagen in solution although in relatively 
high concentrations [4]. This is not a specific finding as it 
is well known that other amino acids can inhibit fibril 
formation of collagen at relatively low concentrations; an 
example is the reaction of the amino groups of arginine 
with the carbonyl/aldehydic residues [7]. Although high 
concentrations of bomocysteine have been reported to 
inhibit lysyl oxidase, such concentrations are unlikely to 
occur in vivo [8]. 
The hypotheses mentioned above and in a recent review 
[9] require confirmation. No in vitro or in vivo studies 
investigating other mechanisms have been published so far 
and, in particular, no work has been reported examining 
collagen synthesis in vivo or in vitro. We therefore studied 
collagen type I synthesis by measuring plasma carboxyter- 
minal propeptide of type I procollagen (PICP), cross-lin- 
ked carboxyterminal telopeptide of collagen type I (ICTP) 
and the synthesis of collagen type III as represented by the 
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N-terminal propeptide of procollagen type III (PIIlNP) in 
plasma. 
We found normal synthetic parameters for collagens 
type I and III but a significant decrease of cross-linked 
carboxyterminal telopeptide of collagen type I in patients 
with homocystinuria. 
2. Patients and methods 
2.1. Patients 
Plasma of 10 patients with hyperhomocysteinemia were 
obtained from a group of patients treated at the University 
Hospital Nijmegen. Nine of them had cystathionine beta 
synthase deficiency and one had the thermolabile form of 
methylenetetrahydrofolate reductase deficiency [10]. Cys- 
tathionine beta synthase deficiency was established by 
severely elevated levels of homocystein and methionine 
and decreased (< 5% of normals) enzyme activity in 
fibroblasts. The clinical characterization is given in Table 
1. 
EDTA blood was drawn and centrifuged 10 min at 
3000 × g within 30 min and stored at - 20°C. 
Plasma of 20 age-matched healthy subjects served as 
controls. 
2.2. Methods 
/zM cysteic acid (Sigma) in 0.1 M HC1 were added as 
internal standard, followed by the addition of 0.1 ml of 3 
M NaBH4 in 0.1 M NaOH mixed with DMSO (2:1 v/v). 
To prevent foaming during the reduction step 30 /zl of 
n-amylalcohol were used. After a 30-rain incubation period 
at 50°C and protein precipitation with 500 /zl of 6% 
perchloric acid, 500 /xl of the supernatant were mixed with 
100 /xl of freshly prepared iodoacetic acid (0.1 M in 9.22 
M borate buffer). After the addition of 100 /xl of 3 M 
NaOH 200 /.d of the obtained solution were derivatized 
with 100 /zl of 400 /~M o-phthalaldehyde solution as 
described elsewhere [12]. 
100-/zl aliquots were injected into the port of the HPLC 
system consisting of the pump system Applied Biosystems 
model 400 and a Spectroflow 980 fluorescence detector. 
The wavelengths used were 230 nm for excitation and 417 
nm for emission. The Shimadzu C-R6A Chromatopac 
integrator was used for data handling. 
A C18 Kromasil 100 analytical (5 /xm) column (250 × 
4.6 mm) was connected to a second column of that kind 
with the dimensions of 150 × 4.6 mm. The mobile phase 
consisted of solvent A (water/sodium propionate 
buf fer /acetoni t r i le  = 60:30:10) and solvent B 
(water/acetonitrile/methanol = 45:30:25). The flow rate 
was 1.3 ml/min during 24 min, then 1.0 ml for 6 min, 1.3 
ml during 22 min and 1.4 ml/min during 10 min. Stan- 
dards used in the experiments were homocysteine hydro- 
chloride, homocysteic acid and cysteic acid, all from Sigma. 
2.2.1. Determination of plasma total homocysteine and 
homocysteic acid levels 
For the HPLC determination the principle of Fermo 
with modifications to allow the concomitant detection of 
homocysteic acid was followed [11]. Briefly, 100 /zl of 
distilled water (HPLC grade Merck, Germany) and 100/xl 
of 9 M urea were added to 100 /zl of plasma. 10 /~1 of 2 
2.2.2. Determination of plasma parameters for collagen 
metabolism and cross-linking 
Commercially available radioimmunoassays for plasma 
carboxyterminal propeptide I(PICP, Orion Diagnostica), 
cross-linked carboxyterminal te opeptide of collagen type I 
(ICTP, Orion Diagnostica) and N-terminal propeptide col- 
lagen type III (PIIINP, Orion Diagnostica) were applied 
Table 1 
Clinical characterization f  patients 
Patient No. Age Sex Height b (cm) Weight b(kg) Marfanoid c Treatment 
At diagnosis a At study Vit B6 Folate Vit B12 Betaine 
1 E53 25 31 m 188 80 - + 
2M61 23 33 m 190 89 + + 
3 B61 26 33 m 191 77 + + + 
4 B58 27 36 m 191 87 + + + 
5 $25 61 65 f 165 d 56 + 
6 V43 e 50 50 m 170 84 - + + 
7 D67 3 27 m 187 77 - + + 
8 D66 4 28 m 184 84 - + + 
9 U78 7 16 f 171 64 - + + 
10 C62 31 31 f 180 63 + 
+ 
+ 
+ + 
+ 
+ 
+ 
a Treatment started since diagnosis except in patient 6. 
b He ight /we ight  at study. 
c Marfanoid because of  dol ichostenomelia, arachnodactyly or thorax deformation. 
d Height in the presence of  kyphoscoliosis. 
e 5-Methylenetetrahydrofotate reductase deficiency because of  thermolabil ity. 
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and the supplier's instructions were followed. 
2.2.3. Statistical calculations 
The Mann-Whitney U-test was used for the comparison 
of groups and linear regression analysis for the correlation 
of data [13]. Statistical significance was accepted at the 
P < 0.05 level. 
Table 3 
Means and S.D. of parameters evaluated in the study 
HC HCA PICP PI I INP ICTP 
p,M/1 /zM/1 /~g/l /~g/1 #g/l 
Patients Means 126.7 8.6 155.3 3.84 1. l 4 
S.D. 75.39 1.17 20.41 0.72 0.24 
Controls Means 12.8 1.53 154.8 3.735 3.29 
S.D. 2.98 0.62 17.6 0.612 0.32 
3.  Resu l t s  
The results are listed in Tables 2 and 3. 
Plasma homocysteine and homocysteic acid were signif- 
icantly higher in the group with homocystinuria. There was 
no correlation between homocyst(e)ine and homocysteic 
acid. 
The collagen synthesis parameters for type I and type 
III collagen did not differ between controls and patients. 
ICTP levels, the plasma parameter for collagen type I 
Table 2 
Results of plasma total homocysteine homocysteic a id and the plasma 
parameters for collagen metabolism and cross-linking 
Patient Homocyst(e)ine Homocysteic PICP " PIIINP b ICTP c 
No. /~M/I acid p~M/l /~g/1 p,g/I /~g/l 
I E53 53 8 146 4.4 1.3 
2 M61 41 9 t52 4.2 
3 B61 101 9 130 2.9 - 
4 B58 79 8 176 4.1 1.4 
5 $25 238 9 184 5.1 1.2 
6 V43 108 6 122 3.3 - 
7 D67 90 8 166 2.9 - 
8 D66 199 10 173 4 0.8 
9 V78 106 10 142 3.3 - 
10 C62 252 9 162 4.2 1 
Controls 
1 16 2 144 4.2 3.2 
2 14 1 162 4.1 3.4 
3 10 1 125 4.3 3.1 
4 12 2 136 2.6 4 
5 16 146 2.7 3.1 
6 13 1 156 3.1 3.2 
7 18 2 170 3.2 3.3 
8 7 1 172 4 3.2 
9 10 2 180 4 3.4 
10 l 1 1 173 4.1 3.5 
11 11 2 142 3.4 3.6 
12 12 3 160 5. l 3.3 
13 14 1 136 4.2 3.2 
14 t6 2 142 3.3 3 
15 15 1 129 3.4 4.1 
16 15 162 3.6 2.9 
17 16 186 3.2 3 
18 12 2 170 4.1 3.1 
19 8 1 164 4 2.9 
20 10 1 141 4.1 3.3 
PICP reflecting collagen type I formation (carboxyterminal propeptide 
of procollagen type I). 
b PIIINP reflecting collagen type III formation (N-terminal propeptide of
procollagen type III). 
c ICTP reflecting collagen type I cross-links (cross-linked carboxytermi- 
hal telopeptide of collagen type I) $ undetectably low. 
cross-linking, however, were significantly lower in the 
patient group and undetectab!y low in half the plasmas 
examined. 
There was no correlation between homocyst(e)ine, ho- 
mocysteic acid and any parameter of collagen metabolism 
and cross-linking. 
4.  D iscuss ion  
In this study, we have demonstrated normal parameters 
for collagen type I and III synthesis but decreased collagen 
cross-linking. 
PICP is nearly an ideal analyte of collagen formation, 
as it is formed and set free in a stoichiometric relationship 
to the amount of type I collagen synthesized and deposited 
in the tissue. Furthermore, the antigen measured in serum 
is homogenous and of the same size as the authentic 
propeptide. Its elimination from serum takes places via 
mannose receptor-mediated endocytosis mainly by the en- 
dothelial cells of the liver [14]. PICP is a reliable indicator 
for collagen synthesis, for example in bone formation; 
good examples are the increase of PICP in bone forming 
metastasis of prostate cancer [15], the decrease of PICP in 
osteoporotic women [16], the decrease of PICP in osteoge- 
nesis imperfecta [17] or the decrease following systemic 
glucocorticoid therapy [18]. In our study no difference 
between plasma PICP of patients with homocystinuria and 
healthy probands was observed, although both compounds, 
homocysteine and homocysteic acid are toxic in higher 
concentrations and thus could have led to inhibition of 
bone collagen synthesis. PIIINP reflecting procollagen type 
III synthesis and studied as a minor collagen in bone but 
major collagen in skin, was unaffected as well. 
ICTP is formed during the maturation of collagen fibres 
and representing type I collagen specific cross-links. This 
cross-linked carboxyterminal te opeptide of collagen type I 
is cleared by the kidneys. Collagen type I degradation 
results in increased serum levels of ICTP correlating with 
calcium kinetics [19] and bone histomorphometric indices 
[20]; good examples are the increased ICTP in breast 
cancer with bone-degrading metastasis, rheumatoid arthri- 
tis with osteolysis [21] or multiple myeloma [22]. In our 
study a significant reduction of plasma ICTP was noted in 
the homocystinuric subjects. However, no correlation be- 
tween homocysteine or homocysteic acid levels and plasma 
ICTP was found. It is possible that, since homocysteine 
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levels were much higher in the cases than controls, a 
threshold effect is operating rather than a dose-response 
effect. Another possibility is that tissue rather than plasma 
homocysteine might correlate better with plasma ICTP. 
The interpretation of these results on ICTP can be 
therefore only speculative. Based on the suggested mecha- 
nism leading to osteoporosis n homocystinuria reduction 
of ICTP must be interpreted as measuring a collagen split 
product with reduced cross-linking, thus fully compatible 
with mechanisms listed in the introduction. The sulfhydryl 
residue of homocysteine is able to block reactive car- 
bonyles representing precursors of collagen cross-links [5]. 
It is therefore not surprising that serum cross-linked car- 
boxyterminal telopeptide of type I collagen is reduced in 
our homocystinuric patients and supports the hypothesis of 
deficient cross-linking in homocystinuria as first proposed 
by McKusick [2]. 
Reduction and subsequent cleaving of disulfide cross- 
links of bone collagen by homocysteine would be an 
alternative mechanism for the development of osteoporosis 
but is not relevant as collagen type I does not contain 
significant cystein residues required for disulfide cross-lin- 
king [23]. 
ICTP is considered a parameter either for collagen 
cross-linking or degradation; we found its reduction and 
interpret he reduction as representing decreased collagen 
cross-links and not decreased degradation of collagen which 
would not fit into the disease, even if a cytotoxic effect of 
homocysteine was taken into consideration [24]. 
Our results show that reduced synthesis of collagens is 
not responsible for osteoporosis n homocystinuria and we 
provide data indicating reduced collagen cross-linking. We 
now propose studying further parameters of impaired 
cross-linking as, e.g., the determination of urinary pyridi- 
noline cross-links which in turn would strengthen the 
cross-linking hypothesis. 
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